April 23rd 2021
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
Multiple Myeloma Therapy on Cusp of New Era, but Much Is Left to Prove, Review Says
December 17th 2020Physicians will soon have a more complex set of options when treating patients with multiple myeloma (MM), but the authors of a new review article argued clinicians will need to take a pragmatic approach.
Read More
BCMA-Targeted CAR T-Cell Therapy Effective in MM, but With Caveats, Analysis Finds
December 16th 2020A new meta-analysis finds high rates of efficacy and high rates of toxicity in multiple myeloma patients treated with B-cell maturation agent (BCMA)-targeted chimeric antigen receptor (CAR)- T cells.
Read More
Exploring Biomarker-Based Risk Stratification in Smoldering Multiple Myeloma
December 9th 2020The science around risk stratification in patients with smoldering multiple myeloma (SMM) has been evolving over the past 2 decades. A new study validates some, though not all, of the proposed biomarkers.
Read More
Considerations for Designing ePRO Interventions for Patients With RRMM
December 4th 2020Patients and health care providers evaluated the use of an electronic patient-reported outcome (ePRO) intervention for use in a clinic setting for patients with relapsed or refractory multiple myeloma (RRMM).
Read More
Use of Triplet Therapy Rose in R/R MM as Deaths Declined, Study Finds
October 29th 2020Newer therapies have led to a boost in the number of patients with relapsed or refractory multiple myeloma (R/R MM) who are prescribed triplet regimens. As that shift has occurred, death rates appear to have dropped.
Read More